{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:30:35Z","timestamp":1793395835844,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:22:58Z","timestamp":1789971778000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of the 5 First-Line Treatment Regimens for Anaplastic-Lymphoma-Kinase-Positive Non-Small Cell Lung Cancer in China: An Economic Evaluation Based on Network Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2026.08.008_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.jval.2026.08.008_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun"},{"issue":"3","key":"10.1016\/j.jval.2026.08.008_bib3","first-page":"167","article-title":"Analysis on the incidence and economic burden of patients with lung cancer","volume":"25","author":"Tian","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"3","key":"10.1016\/j.jval.2026.08.008_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.jval.2026.08.008_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jtho.2020.10.007","article-title":"Outcomes according to ALK status determined by central immunohistochemistry or fluorescence in situ hybridization in patients with ALK-positive NSCLC enrolled in the phase 3 ALEX study","volume":"16","author":"Mok","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.jval.2026.08.008_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.jval.2026.08.008_bib7","first-page":"149","article-title":"Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement","volume":"4","author":"Kim","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.jval.2026.08.008_bib8","first-page":"283","article-title":"Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer","volume":"47","author":"Shi","year":"2025","journal-title":"Chin J Oncol"},{"issue":"11","key":"10.1016\/j.jval.2026.08.008_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/14737140.2023.2265566","article-title":"Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure","volume":"23","author":"Fukuda","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16","key":"10.1016\/j.jval.2026.08.008_bib10","first-page":"1582","article-title":"First-Line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"373","author":"Mok","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jval.2026.08.008_bib11","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jval.2026.08.008_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/curroncol32100542","article-title":"Real-world prevalence, treatment patterns, and economic impact of EGFR- and ALK-targeted therapies in non-small cell lung cancer: a nationwide analysis from Greece","volume":"32","author":"Gourzoulidis","year":"2025","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.08.008_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jcpt.13282","article-title":"A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma","volume":"46","author":"Heo","year":"2020","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.jval.2026.08.008_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1408928","article-title":"First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis","volume":"15","author":"Yi","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jval.2026.08.008_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"21","key":"10.1016\/j.jval.2026.08.008_bib16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2026.08.008_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jval.2026.08.008_bib18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.jval.2026.08.008_bib19","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2026.08.008_bib20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jtho.2024.01.013","article-title":"Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, Phase 3 study (INSPIRE)","volume":"19","author":"Shi","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"15","key":"10.1016\/j.jval.2026.08.008_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025180","article-title":"Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.jval.2026.08.008_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2026.08.008_bib24","series-title":"Chinese Guidelines for Pharmacoeconomic Evaluations. (Chinese-English 2025 Bilingual Edition)","author":"Wu","year":"2025"},{"key":"10.1016\/j.jval.2026.08.008_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"10.1016\/j.jval.2026.08.008_bib27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2217\/pgs-2016-0017","article-title":"Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer","volume":"17","author":"Lu","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.jval.2026.08.008_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.jval.2026.08.008_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2026.08.008_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clinthera.2018.12.007","article-title":"Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small-cell lung cancer in China","volume":"41","author":"Cai","year":"2019","journal-title":"Clin. Ther"},{"issue":"2","key":"10.1016\/j.jval.2026.08.008_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jval.2026.08.008_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40273-018-0625-6","article-title":"Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer","volume":"36","author":"Carlson","year":"2018","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jval.2026.08.008_bib33","article-title":"Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jval.2026.08.008_bib34","article-title":"Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting","volume":"7","author":"Wu","year":"2012","journal-title":"PLoOS One"},{"issue":"5","key":"10.1016\/j.jval.2026.08.008_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/cer-2017-0069","article-title":"Health state utilities in patients with advanced non-small-cell lung cancer in China","volume":"7","author":"Shen","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"5","key":"10.1016\/j.jval.2026.08.008_bib36","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jval.2026.08.008_bib37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40273-020-00954-y","article-title":"Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach","volume":"38","author":"Ochalek","year":"2020","journal-title":"Pharmaco Economics"},{"key":"10.1016\/j.jval.2026.08.008_bib38","article-title":"Chemo-immunotherapy regimes for recurrent or metastatic nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2026.08.008_bib39","article-title":"Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer","volume":"12","author":"Liu","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.jval.2026.08.008_bib40","article-title":"Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jval.2026.08.008_bib41","article-title":"Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France","volume":"15","author":"Sivignon","year":"2020","journal-title":"PLoOS One"},{"issue":"6","key":"10.1016\/j.jval.2026.08.008_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.08.008_bib43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00535-019-01554-0","article-title":"Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan","volume":"54","author":"Kobayashi","year":"2019","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jval.2026.08.008_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4846","article-title":"Cost-effectiveness of Atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.jval.2026.08.008_bib45","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40273-025-01488-x","article-title":"Cost-effectiveness of adjuvant alectinib versus chemotherapy for patients with resectable ALK-positive non-small cell lung cancer in Canada","volume":"43","author":"Jovanoski","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2026.08.008_bib46","first-page":"970","article-title":"The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective","volume":"28","author":"Cranmer","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jval.2026.08.008_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1333487","article-title":"The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China","volume":"12","author":"Dai","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.jval.2026.08.008_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2147\/CEOR.S415711","article-title":"Cost-effectiveness of lorlatinib for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer in Spain","volume":"15","author":"Presa","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.jval.2026.08.008_bib49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jval.2025.03.014","article-title":"First-line alectinib, brigatinib, and lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a cost-effectiveness analysis","volume":"28","author":"Mudumba","year":"2025","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.08.008_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14737167.2023.2288249","article-title":"Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: A cost-effectiveness analysis in Greece","volume":"24","author":"Gourzoulidis","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.jval.2026.08.008_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40258-023-00807-7","article-title":"Cost-effectiveness of lorlatinib in first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive non-small-cell lung cancer in Sweden","volume":"21","author":"Naik","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2026.08.008_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241257234","article-title":"Cost-effectiveness analysis of 6 tyrosine kinase inhibitors as first-line treatment for ALK-positive NSCLC in China","volume":"18","author":"Zhang","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.jval.2026.08.008_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.985834","article-title":"Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China","volume":"10","author":"Luo","year":"2022","journal-title":"Front Public Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526026926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526026926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:39:25Z","timestamp":1793392765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526026926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S1098301526026926"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.08.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of the 5 First-Line Treatment Regimens for Anaplastic-Lymphoma-Kinase-Positive Non-Small Cell Lung Cancer in China: An Economic Evaluation Based on Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}